1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24264
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMitsios, J. V.en
dc.contributor.authorPapathanasiou, A. I.en
dc.contributor.authorElisaf, M. S.en
dc.contributor.authorGoudevenos, J. A.en
dc.contributor.authorTselepis, A. D.en
dc.date.accessioned2015-11-24T19:39:39Z-
dc.date.available2015-11-24T19:39:39Z-
dc.identifier.issn0953-7104-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24264-
dc.rightsDefault Licence-
dc.subjectAcute Diseaseen
dc.subjectAdenosine Diphosphate/*antagonists & inhibitors/pharmacologyen
dc.subjectAgeden
dc.subjectAngioplasty, Balloon, Coronaryen
dc.subjectAnticholesteremic Agents/administration & dosage/*pharmacologyen
dc.subjectBlood Platelets/*drug effects/metabolismen
dc.subjectCD40 Ligand/biosynthesis/blooden
dc.subjectCholesterol/blooden
dc.subjectCholesterol, LDL/blooden
dc.subjectCoronary Disease/blood/*drug therapy/therapyen
dc.subjectDrug Administration Scheduleen
dc.subjectDrug Interactionsen
dc.subjectFemaleen
dc.subjectFlow Cytometryen
dc.subjectHeptanoic Acids/administration & dosage/*pharmacologyen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectP-Selectin/biosynthesis/blooden
dc.subjectPeptide Fragments/pharmacologyen
dc.subjectPlatelet Aggregation/drug effectsen
dc.subjectPlatelet Aggregation Inhibitors/administration & dosage/*pharmacologyen
dc.subjectPyrroles/administration & dosage/*pharmacologyen
dc.subjectTiclopidine/administration & dosage/*analogs & derivatives/pharmacologyen
dc.subjectTriglycerides/blooden
dc.titleThe inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromesen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1080/09537100400028776-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16011979-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2005-
heal.abstractThe antiplatelet potency of clopidogrel may be attenuated by short-term co-administration of lipophilic statins metabolized through the cytochrome P-450, isoform 3A4. We investigated whether the co-administration of atorvastatin (20?mg/day) for 5 weeks, in patients with acute coronary syndromes (ACS) could affect the antiplatelet activity of clopidogrel. Fifty-one patients with the first episode of an ACS were included in the study. All patients underwent percutaneous coronary intervention (PCI) and received a loading dose of 375 mg of clopidogrel, followed by 75 mg/day for at least 3 months. Twenty-six of them presented with low density lipoprotein (LDL) cholesterol levels >100?mg/dl (2.6 mmol/l) (measured within 24 h from the onset of symptoms) and received daily 20 mg/day of atorvastatin. The ADP- or TRAP-induced platelet aggregation, as well as P-selectin and CD40L surface expression, were studied at baseline (within 30 min after admission) and 5 weeks afterwards. Atorvastatin did not influence either the clopidogrel-induced inhibition of platelet aggregation initiated by 5 or 10 microM ADP or the clopidogrel-induced reduction of the membrane expression of P-selectin and CD40L induced by ADP. In conclusion, atorvastatin, even at a dose of 20 mg/day does not affect the antiplatelet efficacy of clopidogrel when co-administered for 5 weeks in ACS patients.en
heal.journalNamePlateletsen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons